Clinical Trial Update: RAD001 and Bicalutamide for Androgen Independent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus (RAD001) in combination with bicalutamide for androgen-independent prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Afinitor (everolimus)
• Casodex (bicalutamide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-03-03